A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

In the US, Wegovy comes in single-use pens. "“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl" was originally created and published by Medical Device Network ...

Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

The next generation of weight-loss drugs aim to help patients lose more weight even faster. CagriSema — developed by Novo Nordisk, the company behind Wegovy — is one example. In a trial last ...

Wegovy's potential successor, CagriSema, came up short of investor expectations in a closely watched Phase 3 trial. Novo's stock has fallen more than 20% over the last year, and people feared ...

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...